As per attachment

GlaxoSmithKline Pharmaceuticals Limited GSK House, Dr. Annie Besant Road, Worli, Mumbai - 400 030 Tel No: +91 22 2495 9595 Fax No: +91 22 2495 9494 Web: www.gsk-india.com Email: askus@gsk.com 26th August 2026 BSE LIMITED THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Phiroze Jeejeebhoy Towers Exchange Plaza, 5th Floor, Plot No. C/1, G Block Dalal Street Bandra-Kurla Complex, Bandra (East) Mumbai - 400001 Mumbai - 400051 Dear Sir, Re: Increase in Volume This is in reference to your email dated today i.e. August 26, 2026, regarding clarification for significant increase in the volume of security across exchanges, in the recent past. We would like to clarify that the Company has made all the necessary disclosures pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 from time to time and has not withheld any material information/ event that in our opinion would have a bearing on the operations/ performance of the Company which include all price sensitive information, etc. The significant increase in the volume of the Company is purely market driven. We would like to reiterate that the Company will continue to comply with the listing regulations requirements and keep the Stock Exchange informed of all price sensitive information as and when they arise. You are requested to please take the above clarification on record and keep the members of the exchange informed. Thanking you, Yours faithfully For GlaxoSmithKline Pharmaceuticals Limited Ajay Nadkarni Vice President - Administration, Real Estate & Company Secretary CIN: L24239MH1924PLC001151